Fan Wu

List of Publications by Year in Descending Order

49 papers	1,183 citations	20 h-index	33 g-index
51 ext. papers	1,986 ext. citations	7.3 avg, IF	4.54 L-index

#	Paper	IF	Citations
49	An MRI radiomics approach to predict survival and tumour-infiltrating macrophages in gliomas.. *Brain*, **2022**,	11.2	5
48	Clinical Characterization and Immunosuppressive Regulation of CD161 (KLRB1) in Glioma through 916 Samples. *Cancer Science*, **2021**,	6.9	4
47	Molecular Characterization and Clinical Relevance of in Gliomas 1,018 Chinese Cohort Patients.. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 777182	5.7	0
46	Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients. *Genomics, Proteomics and Bioinformatics*, **2021**, 19, 1-12	6.5	103
45	Metabolic expression profiling stratifies diffuse lower-grade glioma into three distinct tumour subtypes. *British Journal of Cancer*, **2021**, 125, 255-264	8.7	0
44	A novel DNA repair-related nomogram predicts survival in low-grade gliomas. *CNS Neuroscience and Therapeutics*, **2021**, 27, 186-195	6.8	1
43	Predictive value of MGMT promoter methylation on the survival of TMZ treated -mutant glioblastoma. *Cancer Biology and Medicine*, **2021**, 18, 272-282	5.2	6
42	Norepinephrine in Goal-Directed Fluid Therapy During General Anesthesia in Elderly Patients Undergoing Spinal Operation: Determining Effective Infusion Rate to Enhance Postoperative Functions.. *Current Genomics*, **2021**, 22, 620-629	2.6	
41	Galectin-9/TIM-3 as a Key Regulator of Immune Response in Gliomas With Chromosome 1p/19q Codeletion.. *Frontiers in Immunology*, **2021**, 12, 800928	8.4	2
40	Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma. *Journal of Pathology*, **2020**, 251, 272-283	9.4	19
39	Classification of diffuse lower-grade glioma based on immunological profiling. *Molecular Oncology*, **2020**, 14, 2081-2095	7.9	24
38	Surveying brain tumor heterogeneity by single-cell RNA-sequencing of multi-sector biopsies. *National Science Review*, **2020**, 7, 1306-1318	10.8	15
37	Identification of an ATP metabolism-related signature associated with prognosis and immune microenvironment in gliomas. *Cancer Science*, **2020**, 111, 2325-2335	6.9	14
36	Clinical and Biological Significances of a Methyltransferase-Related Signature in Diffuse Glioma. *Frontiers in Oncology*, **2020**, 10, 508	5.3	2
35	indicates assembly of M0 macrophage and more malignant phenotypes of glioma. *Aging*, **2020**, 12, 8397-8412	3.6	7
34	RPP30, a transcriptional regulator, is a potential pathogenic factor in glioblastoma. *Aging*, **2020**, 12, 16155-16171	5.3	1
33	Characterization and prognostic significance of alternative splicing events in lower-grade diffuse gliomas. *Journal of Cellular and Molecular Medicine*, **2020**, 24, 13171-13180	5.6	2

32	Single-Cell RNA-Sequencing Shift in the Interaction Pattern Between Glioma Stem Cells and Immune Cells During Tumorigenesis. *Frontiers in Immunology*, **2020**, 11, 581209	8.4	10
31	Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma. *Cancer Cell International*, **2019**, 19, 155	6.4	14
30	Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma. *Carcinogenesis*, **2019**, 40, 1229-1239	4.6	29
29	mA RNA methylation regulators contribute to malignant progression and have clinical prognostic impact in gliomas. *Aging*, **2019**, 11, 1204-1225	5.6	125
28	Elevated signature of a gene module coexpressed with CDC20 marks genomic instability in glioma. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 6975-6984	11.5	19
27	Molecular classification of IDH-mutant glioblastomas based on gene expression profiles. *Carcinogenesis*, **2019**, 40, 853-860	4.6	22
26	Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas. *CNS Neuroscience and Therapeutics*, **2019**, 25, 314-322	6.8	20
25	Glioma-associated human endothelial cell-derived extracellular vesicles specifically promote the tumourigenicity of glioma stem cells via CD9. *Oncogene*, **2019**, 38, 6898-6912	9.2	10
24	A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide. *Frontiers in Genetics*, **2019**, 10, 910	4.5	13
23	Prognostic power of a lipid metabolism gene panel for diffuse gliomas. *Journal of Cellular and Molecular Medicine*, **2019**, 23, 7741-7748	5.6	37
22	RNA processing genes characterize RNA splicing and further stratify lower-grade glioma. *JCI Insight*, **2019**, 5,	9.9	13
21	The antibiotic clofoctol suppresses glioma stem cell proliferation by activating KLF13. *Journal of Clinical Investigation*, **2019**, 129, 3072-3085	15.9	20
20	Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy. *OncoTargets and Therapy*, **2019**, 12, 10263-10273	4.4	11
19	Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses. *Frontiers in Oncology*, **2019**, 9, 1433	5.3	8
18	Amino acid metabolism-related gene expression-based risk signature can better predict overall survival for glioma. *Cancer Science*, **2019**, 110, 321-333	6.9	20
17	Acidosis enhances the self-renewal and mitochondrial respiration of stem cell-like glioma cells through CYP24A1-mediated reduction of vitamin D. *Cell Death and Disease*, **2019**, 10, 25	9.8	23
16	A novel analytical model of MGMT methylation pyrosequencing offers improved predictive performance in patients with gliomas. *Modern Pathology*, **2019**, 32, 4-15	9.8	19
15	A comprehensive review of available omics data resources and molecular profiling for precision glioma studies. *Biomedical Reports*, **2019**, 10, 3-9	1.8	5

14	Expression profile analysis of antisense long non-coding RNA identifies WDFY3-AS2 as a prognostic biomarker in diffuse glioma. *Cancer Cell International*, **2018**, 18, 107	6.4	21
13	Identification of an energy metabolism-related signature associated with clinical prognosis in diffuse glioma. *Aging*, **2018**, 10, 3185-3209	5.6	39
12	Long noncoding RNA HOXD-AS2 regulates cell cycle to promote glioma progression. *Journal of Cellular Biochemistry*, **2018**, 120, 8343	4.7	16
11	An immune-related lncRNA signature for patients with anaplastic gliomas. *Journal of Neuro-Oncology*, **2018**, 136, 263-271	4.8	85
10	Bioinformatic analysis of gene expression and methylation regulation in glioblastoma. *Journal of Neuro-Oncology*, **2018**, 136, 495-503	4.8	30
9	ALDH1A3 induces mesenchymal differentiation and serves as a predictor for survival in glioblastoma. *Cell Death and Disease*, **2018**, 9, 1190	9.8	27
8	Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. *Cell*, **2018**, 175, 1665-1678.e18	56.2	125
7	Prognostic value of ion channel genes in Chinese patients with gliomas based on mRNA expression profiling. *Journal of Neuro-Oncology*, **2017**, 134, 397-405	4.8	4
6	Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples. *OncoImmunology*, **2017**, 6, e1328339	7.2	74
5	Upregulation of long noncoding RNA HOXA-AS3 promotes tumor progression and predicts poor prognosis in glioma. *Oncotarget*, **2017**, 8, 53110-53123	3.3	44
4	A PTEN-COL17A1 fusion gene and its novel regulatory role in Collagen XVII expression and GBM malignance. *Oncotarget*, **2017**, 8, 85794-85803	3.3	4
3	A three ion channel genes-based signature predicts prognosis of primary glioblastoma patients and reveals a chemotherapy sensitive subtype. *Oncotarget*, **2016**, 7, 74895-74903	3.3	11
2	LncRNA profile study reveals four-lncRNA signature associated with the prognosis of patients with anaplastic gliomas. *Oncotarget*, **2016**, 7, 77225-77236	3.3	44
1	A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma. *Oncotarget*, **2016**, 7, 69991-69999	3.3	34